CHE · Chemed Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $2.53B | $2.43B | $2.26B | $2.13B | $2.14B | $2.08B |
| Cost of Revenue | $1.71B | $1.58B | $1.47B | $1.37B | $1.37B | $1.38B |
| Gross Profit | $823.18M | $854.35M | $798.82M | $765.09M | $769.80M | $701.39M |
| R&D | - | - | - | - | - | - |
| SG&A | $417.19M | $424.36M | $395.12M | $358.73M | $366.73M | $330.22M |
| Total Operating Expenses | $2.19B | $2.06B | $1.92B | $1.79B | $1.80B | $1.69B |
| D&A | $64.84M | $63.05M | $60.87M | $59.17M | $59.05M | $56.58M |
| Operating Income | $338.25M | $366.49M | $340.57M | $343.50M | $343.04M | $389.68M |
| Interest Expense | $1.75M | $1.78M | $3.11M | $4.58M | $1.87M | $2.35M |
| Income Tax | $90.54M | $97.47M | $77.86M | $80.06M | $81.76M | $76.52M |
| Net Income | $265.24M | $302.00M | $272.51M | $249.62M | $268.55M | $319.47M |
| EPS - Basic | $18.42 | $20.10 | $18.11 | $16.72 | $17.14 | $20.02 |
| EPS - Diluted | $18.34 | $19.89 | $17.93 | $16.53 | $16.85 | $19.48 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $74.52M | $178.35M | $263.96M | $74.13M | $32.90M | $162.68M |
| Accounts Receivable | $182.57M | $171.16M | $181.51M | $139.41M | $137.22M | $126.85M |
| Inventory | $7.54M | $8.19M | $12.00M | $10.27M | $10.11M | $7.09M |
| Accounts Payable | $64.46M | $44.15M | $64.03M | $41.88M | $73.02M | $54.23M |
| Current Assets | $302.62M | $394.75M | $500.84M | $272.61M | $230.29M | $329.40M |
| Total Assets | $1.54B | $1.67B | $1.67B | $1.44B | $1.34B | $1.43B |
| Current Liabilities | $287.13M | $285.69M | $312.05M | $297.20M | $302.40M | $299.11M |
| Long-term Debt | - | - | - | $92.50M | $185.00M | - |
| Total Liabilities | $558.78M | $549.58M | $560.22M | $643.30M | $719.45M | $533.71M |
| Stockholders' Equity | $979.40M | $1.12B | $1.11B | $798.72M | $623.27M | $901.20M |
| Retained Earnings | $2.96B | $2.72B | $2.45B | $2.20B | $1.97B | $1.72B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $388.27M | $417.50M | $330.30M | $309.89M | $308.60M | $489.29M |
| Investing Cash Flow | ($59.34M) | ($143.91M) | ($60.64M) | ($59.40M) | ($57.76M) | ($61.56M) |
| Financing Cash Flow | ($432.77M) | ($359.19M) | ($79.83M) | ($209.25M) | ($380.62M) | ($271.21M) |
| CapEx | $62.80M | $49.53M | $56.85M | $57.33M | $58.67M | $58.83M |
| Free Cash Flow | $325.48M | $367.97M | $273.44M | $252.56M | $249.92M | $430.46M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 32.5% | 35.1% | 35.3% | 35.8% | 36.0% | 33.7% |
| Operating margin | 13.4% | 15.1% | 15.0% | 16.1% | 16.0% | 18.7% |
| EBITDA margin | 15.9% | 17.7% | 17.7% | 18.9% | 18.8% | 21.5% |
| Net margin | 10.5% | 12.4% | 12.0% | 11.7% | 12.6% | 15.4% |
| Free cash flow margin | 12.9% | 15.1% | 12.1% | 11.8% | 11.7% | 20.7% |
| FCF / Net income | 1.23 | 1.22 | 1.00 | 1.01 | 0.93 | 1.35 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 16.5% | 17.5% | 17.4% | 16.8% | 17.1% | 15.9% |
| Effective tax rate | 25.4% | 24.4% | 22.2% | 24.3% | 23.3% | 19.3% |
| Return on assets | 17.2% | 18.1% | 16.3% | 17.3% | 20.0% | 22.3% |
| Return on equity | 27.1% | 27.0% | 24.6% | 31.3% | 43.1% | 35.4% |
| Return on invested capital | - | - | - | 29.2% | 32.5% | - |
| Liquidity | ||||||
| Current ratio | 1.05 | 1.38 | 1.61 | 0.92 | 0.76 | 1.10 |
| Quick ratio | 1.03 | 1.35 | 1.57 | 0.88 | 0.73 | 1.08 |
| Cash ratio | 0.26 | 0.62 | 0.85 | 0.25 | 0.11 | 0.54 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.12 | 0.30 | - |
| Debt / Assets | - | - | - | 0.06 | 0.14 | - |
| Debt / EBITDA | - | - | - | 0.23 | 0.46 | - |
| Interest coverage | 193.3x | 205.9x | 109.6x | 74.9x | 183.6x | 165.5x |
| Equity multiplier | 1.57 | 1.49 | 1.51 | 1.81 | 2.15 | 1.59 |
| Liabilities / Assets | 0.36 | 0.33 | 0.34 | 0.45 | 0.54 | 0.37 |
| Efficiency | ||||||
| Asset turnover | 1.64 | 1.46 | 1.36 | 1.48 | 1.59 | 1.45 |
| Inventory turnover | 226.28 | 192.47 | 122.09 | 133.36 | 135.47 | 194.25 |
| Days sales outstanding | 26d | 26d | 29d | 24d | 23d | 22d |
| Days inventory outstanding | 2d | 2d | 3d | 3d | 3d | 2d |
| Days payable outstanding | 14d | 10d | 16d | 11d | 19d | 14d |
| Cash conversion cycle | 14d | 17d | 16d | 15d | 7d | 10d |
| Valuation | ||||||
| P / E | 23.3x | 26.6x | 32.6x | 30.9x | 31.4x | 27.3x |
| P / B | 6.3x | 7.2x | 8.0x | 9.6x | 13.5x | 9.7x |
| P / S | 2.4x | 3.3x | 3.9x | 3.6x | 3.9x | 4.2x |
| EV / EBITDA | 15.2x | 18.3x | 21.5x | 19.2x | 21.3x | 19.2x |
| Growth | ||||||
| Revenue growth (YoY) | 4.1% | 7.4% | 6.1% | -0.2% | 2.9% | 7.3% |
| Revenue CAGR (3y) | 5.8% | 4.4% | 2.9% | 3.3% | 10.7% | 9.7% |
| Revenue CAGR (5y) | 4.0% | 4.6% | 7.5% | 6.2% | 8.0% | 8.0% |
| Gross profit growth (YoY) | -3.6% | 7.0% | 4.4% | -0.6% | 9.8% | 13.6% |
| Operating income growth (YoY) | -7.7% | 7.6% | -0.9% | 0.1% | -12.0% | 51.4% |
| Net income growth (YoY) | -12.2% | 10.8% | 9.2% | -7.0% | -15.9% | 45.3% |
| EPS growth (YoY) | -7.8% | 10.9% | 8.5% | -1.9% | -13.5% | 46.4% |
| EPS CAGR (3y) | 3.5% | 5.7% | -2.7% | 7.5% | 11.3% | 49.2% |
| EPS CAGR (5y) | -1.2% | 8.4% | 8.0% | 23.0% | 21.1% | 25.2% |
| FCF growth (YoY) | -11.5% | 34.6% | 8.3% | 1.1% | -41.9% | 73.4% |
| FCF CAGR (5y) | -5.4% | 8.2% | 3.1% | 28.9% | 21.2% | 32.2% |
| Book value growth (YoY) | -12.5% | 1.0% | 38.7% | 28.1% | -30.8% | 24.0% |
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
4.70
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Home Health Care Services
Comparing CHEMED CORP against the 5 most active filers in the same SIC group.
Dividends
$2.40/share trailing 12 months · +20.0% YoY
| Ex-date | Per share |
|---|---|
| May 28, 2026 | $0.6000 |
| Feb 23, 2026 | $0.6000 |
| Nov 17, 2025 | $0.6000 |
| Aug 11, 2025 | $0.6000 |
| May 29, 2025 | $0.5000 |
| Feb 24, 2025 | $0.5000 |
| Nov 18, 2024 | $0.5000 |
| Aug 12, 2024 | $0.5000 |
| May 30, 2024 | $0.4000 |
| Feb 23, 2024 | $0.4000 |
| Nov 10, 2023 | $0.4000 |
| Aug 11, 2023 | $0.4000 |
| May 24, 2023 | $0.3800 |
| Feb 24, 2023 | $0.3800 |
| Nov 10, 2022 | $0.3800 |
| Aug 12, 2022 | $0.3800 |
| May 25, 2022 | $0.3600 |
| Feb 25, 2022 | $0.3600 |
| Nov 12, 2021 | $0.3600 |
| Aug 13, 2021 | $0.3600 |
| May 26, 2021 | $0.3400 |
| Feb 26, 2021 | $0.3400 |
| Nov 13, 2020 | $0.3400 |
| Aug 14, 2020 | $0.3400 |